Cell Signaling & Oncology
The signaling pathways controlling cell growth and differentiation are almost invariably altered in cancer. During the course of tumor progression, cancer cells acquire a number of characteristic alterations. These include the capacities to proliferate independently of exogenous growth-promoting or growth-inhibitory signals, to invade surrounding tissues and metastasize to distant sites, to elicit an angiogenic response, and to evade mechanisms that limit cell proliferation, such as apoptosis and replicative senescence. These properties reflect alterations in the cellular signaling pathways that in normal cells control cell proliferation, motility, and survival. These interconnected pathways are being deciphered, but understanding the alterations that lead to cancer and correcting them is a substantial challenge. Among the key pathways are those controlling cell proliferation, which coordinate a response to the cellular environment, with the mTOR kinase as a critical node. Tumour development is influenced by infections and inflammation, and the complex role of the nuclear factor-B transcription factors is being unravelled. Expansion of tumour cells depends on nutrient supply and vascularization, which is orchestrated by the transcription factor known as HIF. And the metastatic spread of primary tumours to other organs is facilitated by many signaling pathways[1],[2].
Cell Signaling and Oncology products Library
For your convenience, you can order a library of all of our Cell Signaling and Oncology research related products. Make your personal library by cherry picking products of your interest from our comprehensive list (>800 products), or order all together not to miss any. The libraries will be shipped as 10 mM solutions (in DMSO, 250 µL of each selected Axon Ligand™) on a 96-well microtiter plate with a clear map of its contents.
Simply download our comprehensive list of epigenetics products below (Microsoft Excel (.xls)), check the products to be included, and return your list to order the library of your preference.
 Axon 5051 - Cell signaling and Oncology Library.xls |
|
[1] A. Eccleston, R. Dhand. Signalling in cancer. Nature 441, 423, editorial note
[2] G.S. Martin. Cell signaling and cancer. Cancer Cell. 2003 Sep;4(3):167-74.
| Axon ID | Name | Description | From price | |
|---|---|---|---|---|
| 1621 | XMD 8-92 trifluoroacetate | BMK1 inhibitor; ERK5 inhibitor | €70.00 | |
| 1846 | XMD 8-92 | BMK1 inhibitor; ERK5 inhibitor | €70.00 | |
| 3836 | VX-11e | Potent, selective, and orally bioavailable inhibitor of ERK2 | Inquire | |
| 1811 | VX 745 | Inhibitor of p38α MAP kinase | €90.00 | |
| 4151 | Ulixertinib hydrochloride | Potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases | Inquire | |
| 2520 | U 0126 | Non-competitive inhibitor of MEK1/2 and protects brain in stroke models | €90.00 | |
| 3282 | Takinib | Potent and selective TAK1 (MAP3K7) inhibitor | €105.00 | |
| 3183 | SR-318 | Highly potent and selective type-II p38 α/β inhibitor | €120.00 | |
| 2365 | SR 3576 | Very potent JNK3 inhibitor with >2800-fold selectivity over p38 | €135.00 | |
| 2519 | SP 600125 | Selective, reversible, and ATP-competitive JNK inhibitor | €70.00 | |
| 1122 | SL 327 | MEK1 and MEK2 inhibitor | €80.00 | |
| 2956 | Selonsertib | Potent, highly selective, orally available, and ATP-competitive ASK1 inhibitor | €90.00 | |
| 1357 | SD 169 | MAPK inhibitor (p38α specific) | €60.00 | |
| 1671 | SCIO 469 | MAPK inhibitor (p38 specific) | €120.00 | |
| 3803 | SCH900353 | ERK1/2 inhibitor | Inquire | |
| 3867 | SCH772984 hydrochloride | Potent, specific and ATP competitive inhibitor of ERK1 and ERK2 | Inquire | |
| 1897 | SB 747651A | Inhibitor of MSK1 | €120.00 | |
| 2444 | SB 706504 | Selective p38 MAPK inhibitor that targets a subset of inflammatory macrophage genes. | €125.00 | |
| 1465 | SB 203580 hydrochloride | MAPK inhibitor (p38 specific) | €70.00 | |
| 1363 | SB 203580 | MAPK inhibitor (p38 specific) | €95.00 | |
| 1364 | SB 202190 | MAPK inhibitor (p38 specific) | €95.00 | |
| 1837 | PH 797804 | Inhibitor of p38α MAPK | €115.00 | |
| 4215 | PF-562271 | Potent, selective, ATP-competitive and reversible dual FAK/PYK2 inhibitor | Recently added | €110.00 |
| 2107 | PF 431396 | Dual FAK(PTK2) and PYK2 inhibitor | €80.00 | |
| 1223 | PD98059 | MEK inhibitor | €80.00 | |
| 1368 | PD184352 | MEK 1 inhibitor | €80.00 | |
| 1365 | PD169316 | MAPK inhibitor (p38 specific) | €95.00 | |
| 1408 | PD0325901 | MEK1 and MEK2 inhibitor | €50.00 | |
| 1814 | NQDI 1 | Inhibitor of apoptosis signal-regulating kinase 1 (ASK1) | €115.00 | |
| 2366 | NG 25 trihydrochloride | Type II inhibitor of TAK1 (MAP3K7) and MAP4K2 (GCK) | €75.00 | |